DE112005000730B4 - Ionen bindende Polymere und ihre Verwendung - Google Patents

Ionen bindende Polymere und ihre Verwendung Download PDF

Info

Publication number
DE112005000730B4
DE112005000730B4 DE112005000730.8T DE112005000730T DE112005000730B4 DE 112005000730 B4 DE112005000730 B4 DE 112005000730B4 DE 112005000730 T DE112005000730 T DE 112005000730T DE 112005000730 B4 DE112005000730 B4 DE 112005000730B4
Authority
DE
Germany
Prior art keywords
polymer
potassium
shell
binding
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE112005000730.8T
Other languages
German (de)
English (en)
Other versions
DE112005000730T5 (de
Inventor
Dominique Charmot
Han Ting Chang
Gerrit Klaerner
Michael James Cope
Mingjun Liu
Futian Liu
Tony Kwok-Kong Mong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Relypsa Inc
Original Assignee
Relypsa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35054544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE112005000730(B4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/814,749 external-priority patent/US8192758B2/en
Priority claimed from US10/814,527 external-priority patent/US7854924B2/en
Priority claimed from US10/813,872 external-priority patent/US8282960B2/en
Application filed by Relypsa Inc filed Critical Relypsa Inc
Publication of DE112005000730T5 publication Critical patent/DE112005000730T5/de
Application granted granted Critical
Publication of DE112005000730B4 publication Critical patent/DE112005000730B4/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F120/04—Acids; Metal salts or ammonium salts thereof
    • C08F120/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F128/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur
    • C08F128/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur by a bond to sulfur
DE112005000730.8T 2004-03-30 2005-03-30 Ionen bindende Polymere und ihre Verwendung Active DE112005000730B4 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US10/813,872 2004-03-30
US10/814,527 2004-03-30
US10/814,749 US8192758B2 (en) 2004-03-30 2004-03-30 Ion binding compositions
US10/814,527 US7854924B2 (en) 2004-03-30 2004-03-30 Methods and compositions for treatment of ion imbalances
US10/814,749 2004-03-30
US10/813,872 US8282960B2 (en) 2004-03-30 2004-03-30 Ion binding compositions
US10/965,274 US7488495B2 (en) 2004-03-30 2004-10-13 Ion binding polymers and uses thereof
US10/965,274 2004-10-13
PCT/US2005/010978 WO2005097081A1 (en) 2004-03-30 2005-03-30 Ion binding polymers and uses thereof

Publications (2)

Publication Number Publication Date
DE112005000730T5 DE112005000730T5 (de) 2008-07-03
DE112005000730B4 true DE112005000730B4 (de) 2017-12-21

Family

ID=35054544

Family Applications (1)

Application Number Title Priority Date Filing Date
DE112005000730.8T Active DE112005000730B4 (de) 2004-03-30 2005-03-30 Ionen bindende Polymere und ihre Verwendung

Country Status (12)

Country Link
US (14) US7776319B2 (US07776319-20100817-C00006.png)
EP (3) EP1732516B1 (US07776319-20100817-C00006.png)
JP (3) JP4964122B2 (US07776319-20100817-C00006.png)
KR (3) KR101199608B1 (US07776319-20100817-C00006.png)
AU (3) AU2005231383B2 (US07776319-20100817-C00006.png)
BR (3) BRPI0509365B8 (US07776319-20100817-C00006.png)
CA (3) CA2557848C (US07776319-20100817-C00006.png)
DE (1) DE112005000730B4 (US07776319-20100817-C00006.png)
GB (3) GB2430624B (US07776319-20100817-C00006.png)
MX (1) MXPA06011270A (US07776319-20100817-C00006.png)
PL (1) PL1732523T3 (US07776319-20100817-C00006.png)
WO (3) WO2005097072A1 (US07776319-20100817-C00006.png)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1660104T3 (da) 2003-08-26 2010-06-21 Shire Holdings Ag Farmaceutisk formulering indeholdende lanthanforbindelser
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
ES2388052T3 (es) * 2004-03-30 2012-10-08 Relypsa, Inc. Polímeros de unión a potasio para su uso en un procedimiento terapéutico o profiláctico para el tratamiento de la hipercalemia
US7776319B2 (en) * 2004-03-30 2010-08-17 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
KR20080059265A (ko) 2005-09-30 2008-06-26 일립사, 인코포레이티드 포유동물의 위장관으로부터 칼륨 이온을 선택적으로제거하기 위한 방법 및 조성물
WO2007038801A2 (en) * 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
GB2446076B (en) * 2005-09-30 2010-11-24 Ilypsa Inc Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
CN100398112C (zh) * 2006-03-24 2008-07-02 辽宁诺康生物制药有限责任公司 一种治疗血磷酸盐过多症的药物及其制备方法
WO2008040556A1 (en) * 2006-10-06 2008-04-10 Scil Technology Gmbh Dried reconstituted vesicle formation for pharmaceutical application
JP5277964B2 (ja) * 2006-12-26 2013-08-28 Ｊｎｃ株式会社 架橋セルロース誘導体の金属塩
EP2107072A1 (en) * 2006-12-26 2009-10-07 Otsuka Pharmaceutical Factory, Inc. Sodium absorption inhibitor, potassium absorption inhibitor, phosphorus absorption inhibitor and preventive agent, therapeutic agent and food containing the same
MX2009011898A (es) * 2007-05-04 2009-11-18 Ironwood Pharmaceuticals Inc Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido.
WO2009029829A1 (en) * 2007-08-29 2009-03-05 Sorbent Therapeutics, Inc. Polymeric compositions with enhanced saline holding capacity and their method of preparation and use
JP5294681B2 (ja) * 2008-04-28 2013-09-18 東京エレクトロン株式会社 基板処理装置及びその基板搬送方法
US8337824B2 (en) * 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
WO2010022381A1 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
EP2957286B1 (en) 2008-08-22 2018-11-21 Vifor (International) Ltd. Compositions comprising crosslinked cation exchange polymers and use in treating hyperkalemia
AU2013204877B2 (en) * 2008-08-22 2015-10-29 Vifor (International) Ltd. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
US20100111892A1 (en) * 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
US20120107381A1 (en) * 2009-05-13 2012-05-03 Relypsa, Inc. Powder formulations of potassium-binding active agents
MX347224B (es) 2010-03-20 2017-04-19 Relypsa Inc Proceso continuo para preparar particulas de polifluoroacrilato.
US9314523B2 (en) 2010-09-21 2016-04-19 Elwha Llc Ingestible salt grabber
RS58490B1 (sr) 2011-02-11 2019-04-30 Zs Pharma Inc Primena cirkonijum silikata za tretman hiperkalemije
WO2013003495A2 (en) 2011-06-27 2013-01-03 Relypsa, Inc. Fluorination of acrylate esters and derivatives
WO2013003463A1 (en) 2011-06-27 2013-01-03 Relypsa, Inc. Process for converting a polymeric ester to a polymeric acid
US9943637B2 (en) 2012-06-11 2018-04-17 ZS Pharma, Inc. Microporous zirconium silicate and its method of production
KR20150036555A (ko) * 2012-07-11 2015-04-07 제트에스 파마, 인코포레이티드 고칼슘혈증 환자에서 고칼륨혈증의 치료를 위한 미세다공성 지르코늄 실리케이트 및 고칼륨혈증의 치료를 위한 개선된 칼슘-함유 조성물
AU2013292350B9 (en) * 2012-07-19 2018-08-23 Vifor Pharma Technology Ltd. Compositions comprising crosslinked cation-binding polymers
CN104603182B (zh) 2012-08-09 2016-11-02 Dpx精细化学奥地利两合公司 干燥聚合材料的方法
WO2014058905A2 (en) 2012-10-08 2014-04-17 Relypsa, Inc. Potassium-binding agents for treating hypertension and hyperkalemia
WO2014066407A1 (en) 2012-10-22 2014-05-01 ZS Pharma, Inc. Microporous zirconium silicate for treating hyperkalemia
US10695365B2 (en) 2012-10-22 2020-06-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
WO2014197725A1 (en) 2013-06-05 2014-12-11 Tricida, Inc. Proton-binding polymers for oral administration
WO2015087985A1 (ja) * 2013-12-11 2015-06-18 株式会社資生堂 腎不全の早期診断マーカー
US9675636B2 (en) * 2014-01-31 2017-06-13 University Of Kansas Micelle sequestering polymers
JP6468780B2 (ja) * 2014-09-30 2019-02-13 積水化成品工業株式会社 中空樹脂粒子及びその製造方法
MA41150B1 (fr) 2014-12-10 2020-06-30 Tricida Inc Polymères de liaison aux protons pour administration orale
US9592253B1 (en) 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
ITUB20159278A1 (it) 2015-12-23 2017-06-23 Rjw Pharma Llc Procedimento per la sintesi di patiromer
MA44875A (fr) 2016-05-06 2019-03-13 Tricida Inc Compositions pour le traitement de troubles acido-basiques
JP2018125951A (ja) * 2017-01-31 2018-08-09 日本電産株式会社 モータ及びそれを備えた送風装置
AU2018360867A1 (en) 2017-11-03 2020-04-30 Tricida, Inc. Compositions for and method of treating acid-base disorders
JP7365631B2 (ja) * 2019-09-02 2023-10-20 国立大学法人福井大学 ホスホン酸又はホスホン酸エステル構造を有するコア－シェル型高分子微粒子、粒子分散液、成形体及び前記微粒子の製造方法
CN113244339B (zh) * 2021-06-04 2021-09-24 南京厚生药业有限公司 一种用于高脂血症的考来烯胺散及其制备方法
US20240139234A1 (en) * 2021-11-17 2024-05-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Pharmaceutical polymer for treating hyperkalemia and preparation method thereof
WO2024035944A1 (en) * 2022-08-12 2024-02-15 University Of Kansas Extraction of critical minerals using polyanions

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427794A (en) 1980-08-22 1984-01-24 Bayer Aktiengesellschaft Process for the preparation of bead polymers of uniform particle size by polymerization of microencapsulated monomer
US4675140A (en) 1984-05-18 1987-06-23 Washington University Technology Associates Method for coating particles or liquid droplets
US4837015A (en) * 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
EP0373852A2 (en) 1988-12-13 1990-06-20 Smith Kline & French Laboratories Limited Compounds
EP0415214A2 (de) 1989-09-01 1991-03-06 Bayer Ag Verfahren zur Herstellung von alpha-Fluoracrylsäurederivaten
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
US5374422A (en) 1989-07-19 1994-12-20 Lowchol Scientific, Inc. Ingestible [hydrophobic] polymeric amines useful for lowering blood cholesterol
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
WO1997049387A1 (en) * 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US6294163B1 (en) 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US6475510B1 (en) 1997-12-19 2002-11-05 Smithkline Beecham Corporation Process for manufacturing bite-dispersion tablets

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2340111A (en) * 1942-07-03 1944-01-25 Gen Electric Process for removing cations from liquid media
US2611730A (en) 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
US2798053A (en) * 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3499960A (en) 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
FR2171934B1 (US07776319-20100817-C00006.png) 1972-02-16 1974-09-13 Rhone Poulenc Sa
US3974272A (en) 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4143130A (en) 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4470975A (en) 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4380590A (en) 1978-09-19 1983-04-19 Rohm And Haas Company Emulsion copolymer cation exchange resins
US4191812A (en) * 1978-09-19 1980-03-04 Rohm And Haas Company Ion exchange process involving emulsion ion exchange resins
SE8003805L (sv) 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
US4362711A (en) 1980-07-11 1982-12-07 Evreka Inc. Blood cholesterol level reducing agent and method
DE3149136A1 (de) 1981-12-11 1983-06-23 Robert Bosch Gmbh, 7000 Stuttgart Einrichtung zur regelung des kraftstoff-luftverhaeltnisses bei brennkraftmaschinen
JPS6090243A (ja) 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
US5238924A (en) * 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors
US4747881A (en) 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US5186937A (en) 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
IT1190349B (it) 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
JPS63218713A (ja) 1987-02-17 1988-09-12 Daikin Ind Ltd α−フルオロアクリル酸系重合体ならびに用途
US5210079A (en) * 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
FR2634377B1 (fr) * 1988-06-30 1991-09-27 Cortial Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif
GB8817015D0 (en) 1988-07-16 1988-08-17 Reckitt & Colmann Prod Ltd Method of treatment
US5091175A (en) 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
ATE116859T1 (de) * 1990-07-04 1995-01-15 Marcin Krotkiewski Blutdrucksenkendes präparat.
IE914179A1 (en) 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5281631A (en) 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
ES2080549T3 (es) * 1992-03-28 1996-02-01 Hoechst Ag Medicamentos a base de derivados de polihidroximetileno, procedimiento para su preparacion y empleo.
HUT72658A (en) 1992-08-20 1996-05-28 Du Pont Crosslinked polymeric ammonium salts and pharmaceutical compositions containing them
WO1994027619A1 (en) 1993-05-20 1994-12-08 Geltex Pharmaceuticals, Inc. Process for adjusting ion concentration in a patient and compositions therefor
US5487888A (en) 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5618530A (en) 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
DE69316933T2 (de) * 1993-11-25 1998-05-28 Salternate B V Teilchen zum binden monovalenten kationen und ihre verwendung
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US5824339A (en) 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
JP3885130B2 (ja) 1996-06-11 2007-02-21 株式会社大塚製薬工場 グアニジノ化合物低下剤並びに水分及びカリウムイオン吸着剤
PT1014941E (pt) 1996-06-26 2009-07-08 Univ Texas Formulação farmacêutica extrudível por termofusão
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5935599A (en) 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
JPH10130154A (ja) 1996-10-29 1998-05-19 Otsuka Pharmaceut Factory Inc 腎疾患患者用延命率改善薬
KR100440544B1 (ko) 1998-07-31 2004-07-15 니켄 가가쿠 가부시키가이샤 양이온 교환수지 제제
WO2000027380A2 (en) * 1998-11-06 2000-05-18 G.D. Searle & Co. Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
CA2355829A1 (en) * 1999-01-07 2000-07-13 Louise Templeton Multiparticulate oral dosage forms
US6558665B1 (en) 1999-05-18 2003-05-06 Arch Development Corporation Encapsulating particles with coatings that conform to size and shape of the particles
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
EP1249240A4 (en) 2000-01-14 2003-03-19 Otsuka Pharma Co Ltd SODIUM ION ABSORPTION INHIBITORS, AND PROPHYLAXIS OR MEDICINAL PRODUCTS AND FOODS THAT CONTAIN THEIR
FR2812632B1 (fr) 2000-08-07 2003-03-07 Solvay Procede pour la synthese de composes fluoroorganiques
CA2428800C (en) 2000-11-20 2011-09-13 Dow Global Technologies Inc. In vivo use of fluid absorbent polymers
US20040105895A1 (en) 2001-02-06 2004-06-03 Ash Stephen R Monovalent-selective cation exchangers as oral sorbent therapy
US7033639B2 (en) 2001-05-16 2006-04-25 Rohm And Haas Company Polyaniline coating composition
US6881484B2 (en) 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
JP2004149525A (ja) 2002-10-09 2004-05-27 Sekisui Chem Co Ltd カリウムイオン吸着剤及びその製造方法、並びに高カリウム血症治療剤
JP5826445B2 (ja) 2003-02-25 2015-12-02 フィンフィーズ フィンランド オイ 擬似移動床システム及び方法
WO2005065291A2 (en) 2003-12-31 2005-07-21 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
US7776319B2 (en) 2004-03-30 2010-08-17 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US7854924B2 (en) * 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7429394B2 (en) * 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
GB2446076B (en) * 2005-09-30 2010-11-24 Ilypsa Inc Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
KR20080059265A (ko) * 2005-09-30 2008-06-26 일립사, 인코포레이티드 포유동물의 위장관으로부터 칼륨 이온을 선택적으로제거하기 위한 방법 및 조성물
US20100111892A1 (en) * 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
WO2010022381A1 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US8337824B2 (en) * 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427794A (en) 1980-08-22 1984-01-24 Bayer Aktiengesellschaft Process for the preparation of bead polymers of uniform particle size by polymerization of microencapsulated monomer
US4675140A (en) 1984-05-18 1987-06-23 Washington University Technology Associates Method for coating particles or liquid droplets
US4837015A (en) * 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
EP0373852A2 (en) 1988-12-13 1990-06-20 Smith Kline & French Laboratories Limited Compounds
US5374422A (en) 1989-07-19 1994-12-20 Lowchol Scientific, Inc. Ingestible [hydrophobic] polymeric amines useful for lowering blood cholesterol
EP0415214A2 (de) 1989-09-01 1991-03-06 Bayer Ag Verfahren zur Herstellung von alpha-Fluoracrylsäurederivaten
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
WO1997049387A1 (en) * 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US6475510B1 (en) 1997-12-19 2002-11-05 Smithkline Beecham Corporation Process for manufacturing bite-dispersion tablets
US6294163B1 (en) 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core

Non-Patent Citations (28)

* Cited by examiner, † Cited by third party
Title
Agarwal, R, et al. (1994) Gastroenterology 107: 548-571
Benoit J.P. et al, J. Microencapsulation, 2003, 20(1)87-128
Bogachev et al, Zhurnal Organisheskoi Khimii, 1986, 22(12), 2578-83
Breslow et al (J. Am. Chem. Soc., 1954, 76, 6399-6401)
Chen, L. et al, Macromolecules (1998), 31(3), 787-794
Figuly et al, Macromolecules, 1997, 30, 6174-6184
G. Van den Mooter, C. Samyn, and R. Kinget, International Journal of Pharmaceutics, 111, 127-136 (1994)
Gassen et al, J. Fluorine Chemistry, 55, (1991) 149-162
Gennaro AR (Hg.), Remington's Pharmaceutical Sciences, 20. Auflage
Hazell, T (1985) World Rev Nutr Diet 46: 1-123
Helfferich, F. "Ion Exchange" (1962) McGraw-Hill, New York
Hunt, CD and Meacham, SL (2001) J Am Diet Assoc 101: 1058-1060
Ichekawa H. et al, International Journal of Pharmaceuticals, 216(2001), 67-76
Kaneko et al, Macromolecular Rapid Communications (2003), 24(13), 789-792
KF Pittman, C. U., M. Ueda, et al. (1980)
Krajewska, B., Reactive and Functional polymers 47, 2001, 37-47
Leach, K. et al., J. Microencapsulation, 1999, 16(2), 153-167
Macromolecules 13(5): 1031-1036
Mandal, A.K. 1997. Hypokalemia and hyperkalemia. Med Clin North Am. 81:611-39
Mandal, AK (1997) Med Clin North Am 81: 611-639
Nightingale E.R., J. Phys. Chem., 63, (1959), 1381-89
Pedersen, C.J. 1987. Charles J. Pederson - Nobel Lecture. The discovery of crown ethers: In Nobel Lectures, Chemistry 1981-1990. T. Frangsmyr, Hg. World Scientific Publishing Co., Singapur
Sata et al, J.Membrane Science, 206 (2002), 31-60
Sata et al., Die Angewandte Makromolekulare Chemie 171, (1989) 101-117 (Nr. 2794)
Schwartz, MW (1987) Am J Nurs 87: 1292-1299
Stover H. et al, Macromolecules, 1999, 32, 2838-2844
The Science and Practice of Pharmacy by A.R. Gennaro (Herausgeber), 20. Auflage, 2000
W. Jost, Diffusion in Solids, Liquids and Gases, Acad. Press, New-York, 1960

Also Published As

Publication number Publication date
US20080233073A1 (en) 2008-09-25
JP4974882B2 (ja) 2012-07-11
EP1732516A1 (en) 2006-12-20
MXPA06011270A (es) 2007-03-08
DE112005000730T5 (de) 2008-07-03
AU2005228696B2 (en) 2010-06-24
WO2005097081A1 (en) 2005-10-20
US20130272990A1 (en) 2013-10-17
GB2430367B (en) 2009-08-05
US20080241093A1 (en) 2008-10-02
JP5000480B2 (ja) 2012-08-15
BRPI0509331B1 (pt) 2018-11-27
GB2430368B (en) 2009-08-26
JP2007531774A (ja) 2007-11-08
WO2005097072A1 (en) 2005-10-20
US20130272991A1 (en) 2013-10-17
JP2007531726A (ja) 2007-11-08
BRPI0509366A (pt) 2007-09-04
EP1732524A4 (en) 2007-09-19
CA2557848C (en) 2013-12-10
US8287847B2 (en) 2012-10-16
US20140286891A1 (en) 2014-09-25
US8778324B2 (en) 2014-07-15
US20110033505A1 (en) 2011-02-10
US20090148533A1 (en) 2009-06-11
AU2005231383B2 (en) 2010-06-10
BRPI0509365B1 (pt) 2018-06-12
US20160317572A1 (en) 2016-11-03
US20080241092A1 (en) 2008-10-02
GB0621241D0 (en) 2006-12-13
BRPI0509366B1 (pt) 2018-07-24
GB0621244D0 (en) 2006-12-13
JP2007531758A (ja) 2007-11-08
AU2005228696A1 (en) 2005-10-13
CA2557999A1 (en) 2005-10-13
JP4964122B2 (ja) 2012-06-27
CA2557848A1 (en) 2005-10-20
KR101199608B1 (ko) 2012-11-08
EP1732524B1 (en) 2012-08-22
GB2430624A (en) 2007-04-04
KR101228233B1 (ko) 2013-01-31
EP1732523B1 (en) 2010-03-17
BRPI0509365A (pt) 2007-09-04
US20200085856A1 (en) 2020-03-19
WO2005094384A2 (en) 2005-10-13
US20110206631A1 (en) 2011-08-25
EP1732523A1 (en) 2006-12-20
EP1732516A4 (en) 2007-06-06
US20160082039A1 (en) 2016-03-24
GB2430368A (en) 2007-03-28
US10485821B2 (en) 2019-11-26
US8282913B2 (en) 2012-10-09
US20060024265A1 (en) 2006-02-02
BRPI0509366B8 (pt) 2021-05-25
KR20070007168A (ko) 2007-01-12
US8445014B2 (en) 2013-05-21
US8889115B2 (en) 2014-11-18
US7776319B2 (en) 2010-08-17
GB2430367A (en) 2007-03-28
KR20060135045A (ko) 2006-12-28
GB0621242D0 (en) 2006-12-13
CA2557999C (en) 2013-11-12
US20130272992A1 (en) 2013-10-17
PL1732523T3 (pl) 2010-08-31
AU2005231424A1 (en) 2005-10-20
KR101153035B1 (ko) 2012-06-11
US8216560B2 (en) 2012-07-10
US8475780B2 (en) 2013-07-02
BRPI0509331A (pt) 2007-09-04
AU2005231424B2 (en) 2010-06-17
WO2005094384A3 (en) 2006-01-26
CA2558029A1 (en) 2005-10-20
KR20060135044A (ko) 2006-12-28
EP1732524A2 (en) 2006-12-20
BRPI0509365B8 (pt) 2021-05-25
EP1732523B9 (en) 2010-06-02
EP1732523A4 (en) 2007-06-06
US8409561B2 (en) 2013-04-02
AU2005231383A1 (en) 2005-10-20
GB2430624B (en) 2009-08-05
BRPI0509331B8 (pt) 2021-05-25
EP1732516B1 (en) 2009-12-30
CA2558029C (en) 2013-05-07

Similar Documents

Publication Publication Date Title
DE112005000730B4 (de) Ionen bindende Polymere und ihre Verwendung
US7556799B2 (en) Ion binding polymers and uses thereof
DE112006002617T5 (de) Verfahren zur Herstellung von Core-Shell-Kompositen bzw. Kern-Hüllen-Kompositen mit vernetzten Hüllen und daraus entstehende Core-Shell-Komposite
DE112006002618T5 (de) Verfahren und Zusammensetzungen zum selektiven Entfernen von Kaliumionen aus dem Gastrointestinaltrakt eines Säugers
AU2016216697C1 (en) Ion binding polymers and uses thereof

Legal Events

Date Code Title Description
8127 New person/name/address of the applicant

Owner name: RELYPSA, INC., SANTA CLARA, CALIF., US

R012 Request for examination validly filed

Effective date: 20120328

R082 Change of representative

Representative=s name: EISENFUEHR SPEISER PATENTANWAELTE RECHTSANWAEL, DE

R081 Change of applicant/patentee

Owner name: RELYPSA, INC., US

Free format text: FORMER OWNER: RELYPSA, INC., SANTA CLARA, US

Effective date: 20131210

Owner name: RELYPSA, INC. (N.D.GES.D. STAATES DELAWARE), US

Free format text: FORMER OWNER: RELYPSA, INC., SANTA CLARA, US

Effective date: 20131210

Owner name: RELYPSA, INC. (N.D.GES.D. STAATES DELAWARE), R, US

Free format text: FORMER OWNER: RELYPSA, INC., SANTA CLARA, CALIF., US

Effective date: 20131210

R082 Change of representative

Representative=s name: EISENFUEHR SPEISER PATENTANWAELTE RECHTSANWAEL, DE

Effective date: 20131210

R082 Change of representative

Representative=s name: EISENFUEHR SPEISER PATENTANWAELTE RECHTSANWAEL, DE

R081 Change of applicant/patentee

Owner name: RELYPSA, INC. (N.D.GES.D. STAATES DELAWARE), US

Free format text: FORMER OWNER: RELYPSA, INC., REDWOOD CITY, US

Effective date: 20140210

Owner name: RELYPSA, INC. (N.D.GES.D. STAATES DELAWARE), R, US

Free format text: FORMER OWNER: RELYPSA, INC., REDWOOD CITY, CALIF., US

Effective date: 20140210

R082 Change of representative

Representative=s name: EISENFUEHR SPEISER PATENTANWAELTE RECHTSANWAEL, DE

Effective date: 20140210

R016 Response to examination communication
R079 Amendment of ipc main class

Free format text: PREVIOUS MAIN CLASS: A61K0009320000

Ipc: A61K0031740000

R018 Grant decision by examination section/examining division
R130 Divisional application to

Ref document number: 112005003883

Country of ref document: DE

R020 Patent grant now final